TABLE 2.

PLASMIC score, ADAMTS13 activity, and distribution of clinical diagnoses.

	PLASMIC score risk prediction (n = 24)
	Low riska (n = 6)	Intermediate riskb (n = 8)	High riskc (n = 10)
ADAMTS13 activity ≤10%, n (%)	0	0	9 (90)
ADAMTS13 activity >10%, n (%)	6 (100)	8 (100)	1 (10)
Clinical diagnosis, n (%)
TTP	0	0	9 (90)
Other TMA
aHUS	0	1 (12.5)	0
SLE-associated TMA	1 (16.7)	4 (50)	0
DI-TMA	2 (33.3)	0	0
TA-TMA	2 (33.3)	0	0
Malignant hypertension	0	1 (12.5)	0
Unexplained TMA	1(16.7)	2 (25)	0
Malignancy	0	0	1(10)

^aLow risk: PLASMIC score of 0–4.

^bIntermediate risk: PLASMIC score of 5.

^cHigh risk: PLASMIC score of 6–7.

ADAMTS13, a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13; TTP, thrombotic thrombocytopenic purpura; TMA, thrombotic microangiopathy; aHUS, atypical hemolytic uremic syndrome; SLE, systemic lupus erythematosus; DI-TMA, drug-induced thrombotic microangiopathy; TA-TMA, transplant-associated thrombotic microangiopathy.